Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a hypothetical or non-standard combination of three nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen, indomethacin, and naproxen. All three are small molecule NSAIDs commonly used individually to reduce pain, inflammation, and fever by inhibiting cyclooxygenase (COX) enzymes involved in prostaglandin synthesis. Each drug is effective as an analgesic and anti-inflammatory agent but combining multiple NSAIDs is not recommended due to a significantly increased risk of adverse effects such as gastrointestinal bleeding, renal impairment, and cardiovascular events. There are no known approved pharmaceutical products or clinical guidelines supporting the use of this triple combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + indomethacin + naproxen.